The FINANCIAL — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced on November 22 to introduce its new blood gas analyzer, the cobas b 123 POC system, in Europe and several markets in Latin America, Middle East, Africa and the Asia-Pacific region.
"The cobas b 123 POC system is a fast, multi-parameter analyzer, delivering many of the vital results that physicians need in order to make decisions in time critical situations. From one drop of blood the system can assess a patient’s oxygenation and acid/base status as well as deliver important information on electrolytes and the metabolites glucose and lactate within 2 minutes," Roche informs.
The new portable analyzer is designed for use in intensive care units for monitoring of blood gases mainly to determine whether a patient is receiving sufficient respiratory support, in emergency departments for patients suffering from heavy trauma or acute heart and lung diseases, operating rooms during surgery and other clinical areas including neonatal and dialysis units.
“Blood gas analyzers must be particularly fast and reliable,” said Daniel O’Day, Head of Roche’s Diagnostic Division. “Roche has designed the easy-to-use cobas b 123 POC system in order to meet the needs of a broad range of clinical settings, where high quality results for immediate medical decisions and treatment adjustments are needed.”
The nearly maintenance free new system expands the portfolio of existing Roche blood gas solutions. Globally, blood gas testing is the biggest segment within hospital point of care testing with a volume of one billion US $ a year.
Discussion about this post